138 related articles for article (PubMed ID: 23107871)
21. Evaluation of vardenafil and sildenafil on cardiac repolarization.
Morganroth J; Ilson BE; Shaddinger BC; Dabiri GA; Patel BR; Boyle DA; Sethuraman VS; Montague TH
Am J Cardiol; 2004 Jun; 93(11):1378-83, A6. PubMed ID: 15165918
[TBL] [Abstract][Full Text] [Related]
22. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.
Milic M; Bao X; Rizos D; Liu F; Ziegler MG
Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469
[TBL] [Abstract][Full Text] [Related]
23. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
Wang Z; Grasela DM; Krishna G
Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies.
Florian JA; Tornøe CW; Brundage R; Parekh A; Garnett CE
J Clin Pharmacol; 2011 Aug; 51(8):1152-62. PubMed ID: 21228407
[TBL] [Abstract][Full Text] [Related]
25. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.
Graham RA; Hop CE; Borin MT; Lum BL; Colburn D; Chang I; Shin YG; Malhi V; Low JA; Dresser MJ
Br J Clin Pharmacol; 2012 Nov; 74(5):788-96. PubMed ID: 22458643
[TBL] [Abstract][Full Text] [Related]
26. Statistical issues of QT prolongation assessment based on linear concentration modeling.
Tsong Y; Shen M; Zhong J; Zhang J
J Biopharm Stat; 2008; 18(3):564-84. PubMed ID: 18470764
[TBL] [Abstract][Full Text] [Related]
27. Effects of three fluoroquinolones on QT interval in healthy adults after single doses.
Noel GJ; Natarajan J; Chien S; Hunt TL; Goodman DB; Abels R
Clin Pharmacol Ther; 2003 Apr; 73(4):292-303. PubMed ID: 12709719
[TBL] [Abstract][Full Text] [Related]
28. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam.
Das S; Armstrong J; Mathews D; Li J; Edeki T
J Clin Pharmacol; 2014 Mar; 54(3):331-40. PubMed ID: 24150927
[TBL] [Abstract][Full Text] [Related]
29. Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors.
Quinlan M; Zhou J; Hurh E; Sellami D
Eur J Clin Pharmacol; 2016 Dec; 72(12):1427-1432. PubMed ID: 27663457
[TBL] [Abstract][Full Text] [Related]
30. Statistical characteristics of moxifloxacin-induced QTc effect.
Yan LK; Zhang J; Ng MJ; Dang Q
J Biopharm Stat; 2010 May; 20(3):497-507. PubMed ID: 20358432
[TBL] [Abstract][Full Text] [Related]
31. Repeated supratherapeutic dosing of strontium ranelate over 15 days does not prolong QT(c) interval in healthy volunteers.
Taubel J; Naseem A; Wang D; Arezina R; Lorch U; Camm AJ
Br J Clin Pharmacol; 2012 Aug; 74(2):296-303. PubMed ID: 22283848
[TBL] [Abstract][Full Text] [Related]
32. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.
Démolis JL; Kubitza D; Tennezé L; Funck-Brentano C
Clin Pharmacol Ther; 2000 Dec; 68(6):658-66. PubMed ID: 11180026
[TBL] [Abstract][Full Text] [Related]
33. Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies.
Sarapa N; Nickens DJ; Raber SR; Reynolds RR; Amantea MA
Clin Pharmacol Ther; 2008 Jan; 83(1):153-9. PubMed ID: 17581594
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron.
Mason JW; Selness DS; Moon TE; O'Mahony B; Donachie P; Howell J
Clin Cancer Res; 2012 May; 18(10):2913-21. PubMed ID: 22452942
[TBL] [Abstract][Full Text] [Related]
35. Evaluating Potential QT Effects of JNJ-54861911, a BACE Inhibitor in Single- and Multiple-Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration-QTc Analysis.
Timmers M; Sinha V; Darpo B; Smith B; Brown R; Xue H; Ferber G; Streffer J; Russu A; Tritsmans L; Solanki B; Bogert J; Van Nueten L; Salvadore G; Nandy P
J Clin Pharmacol; 2018 Jul; 58(7):952-964. PubMed ID: 29505101
[TBL] [Abstract][Full Text] [Related]
36. Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals.
Hoch M; Darpo B; Brossard P; Zhou M; Stoltz R; Dingemanse J
Basic Clin Pharmacol Toxicol; 2015 May; 116(5):429-37. PubMed ID: 25287214
[TBL] [Abstract][Full Text] [Related]
37. Effects of the selective alpha 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controlled study.
Morganroth J; Lepor H; Hill LA; Volinn W; Hoel G
Clin Pharmacol Ther; 2010 May; 87(5):609-13. PubMed ID: 20220748
[TBL] [Abstract][Full Text] [Related]
38. Effect of pomaglumetad methionil on the QT interval in subjects with schizophrenia.
Zhang W; Mitchell MI; Knadler MP; Long A; Witcher J; Walling D; Annes W; Ayan-Oshodi M
Int J Clin Pharmacol Ther; 2015 Jun; 53(6):462-70. PubMed ID: 25881753
[TBL] [Abstract][Full Text] [Related]
39. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.
Chatterjee DJ; Khutoryansky N; Zdravkovic M; Sprenger CR; Litwin JS
J Clin Pharmacol; 2009 Nov; 49(11):1353-62. PubMed ID: 19737980
[TBL] [Abstract][Full Text] [Related]
40. Thorough QT/QTc study of ritonavir-boosted saquinavir following multiple-dose administration of therapeutic and supratherapeutic doses in healthy participants.
Zhang X; Jordan P; Cristea L; Salgo M; Farha R; Kolis S; Lee LS
J Clin Pharmacol; 2012 Apr; 52(4):520-9. PubMed ID: 21558456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
